期刊文献+

宫颈鳞癌组织中PD-ECGFmRNA与PD-ECGF的表达及临床意义 被引量:3

Expression and Its Clinical Significance of PD-ECGFmRNA and PD-ECGF Protein in Cervical Squamous Cell Carcinoma
下载PDF
导出
摘要 目的:研究PD ECGF与宫颈鳞癌发生与发展的关系及作用机制。方法:采用原位杂交和免疫组化法,对87例宫颈鳞癌和2 3例正常及慢性宫颈炎组织PD ECGFmRNA、PD ECGF蛋白进行检测。结果:①PD ECGF在宫颈鳞癌细胞及间质细胞中均有表达,表达率分别为6 2 .0 7%、2 3.2 0 %。PD ECGFmRNA主要在宫颈鳞癌细胞中表达,表达率为5 7.4 7%。二者与宫颈鳞癌临床分期、组织分化程度明显相关(P <0 .0 5 )。②一致性检测发现宫颈鳞癌组织中PD ECGF基因的免疫组化与原位杂交检测结果关系密切(P <0 .0 1 )。结论:①PD ECGF由宫颈鳞癌细胞产生,在间质内发挥作用。②PD ECGF与宫颈鳞癌的发生、发展有密切关系,可作为判断宫颈鳞癌生物学行为和预后的重要指标。 Objective: To study the relationship between PD-ECGF expression and the pathogenesis and development of cervical squamous cell carcinoma. Methods:By using of in situ hybridization and immunohistochemistry, the PD-ECGF gene (PD-ECGFmRNA and PD-ECGF protein) were detected in 87 samples of cervical squamous cell carcinoma and 23 samples of normal cervical tissues and/or chronic cervicitis. Results:① The expression rate of PD-ECGF protein in squamous cell and stroma of cervical carcinoma was 62.07% and 23.20%, respectively. PD-ECGFmRNA mainly expressed in squamous cell and the expression rate was 57.47%. PD-ECGF protein and PD-ECGFmRNA were positively associated with tissue differentiation and clinical stage of cervical squamous cell carcinoma (P<0.05). ② The expression of PD-ECGF protein level was significantly correlated with that at mRNA level (P<0.01). Conclusions: ① PD-ECGF was produced in cervical squamous cell, but play a role in stroma cell. ② PD-ECGF is closely related to the pathogenesis and development of cervical squamous cell carcinoma, and can be a marker to ensure its biological behaviour and prognosis.
作者 于黎明 胡蓉
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2005年第3期151-153,i001,共4页 Journal of Practical Obstetrics and Gynecology
基金 宁夏自然科学基金 (A40 1 9)
关键词 宫颈鳞癌 血小板源性内皮生长因子 原位杂交 免疫组化 Cervical squamous cell carcinoma Platelet-derived endothelial cell growth factor In situ hybridization Immunohistochemistry
  • 相关文献

参考文献6

  • 1Tokumo K,Kodama J,Seki N,et al.Different angiogenic pathways in human cervical cancers.Gynecol Oncol,1998,68:38.
  • 2Nicholas S.Brown ,Adam Jones,et al.Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.Cancer Res,2000,60:6298.
  • 3Kodam J,Yoshinouchi M,Saeki N,et al.Angiogenesia and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.Int J Oncol,1999,15:149.
  • 4Saeki T,Tanada M,Takashima S,et al.Correlation between expression of platelet-derived endothelial cell growth factor(thymidine phosphorylase)and microveasel density in early-stage human colon carcinomas.Jpn Oncol,1997,27:227.
  • 5Robert W.Jyung,MD;Elizabeth E.Leclair,et al.Expression of angiogenic growth factors in paragangliomas.The Laryngoscope,2000,110:161.
  • 6吴志华,高秀艳,刘铁英,田雪红.子宫颈癌组织中促血管生成因子的表达及其与新生血管形成的关系[J].中华妇产科杂志,2003,38(1):41-42. 被引量:5

共引文献4

同被引文献19

  • 1翁练斌,张国玲.术前化疗对巨块型宫颈癌ⅠB-ⅡB期的疗效评价[J].临床肿瘤学杂志,1998,3(2):20-22. 被引量:4
  • 2[1]Relf M,LeJeune S,Scott PA,et al.Expression of the angiogenic factors vascular endothelial cell growth factor,acidic and basic fibroblast growth factor,t umor growth factor beta-l,plalelet-derived endothelial cell growth factor,placenta growth factor,and pleiotrophin in human primary breast cancer and its relation to angiogenesis[J].Cancer Res,1997,57(5):963-969.
  • 3Leitzel K,Teramoto Y,Sampson E,et al.Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.J Clin Oncol,1992,10:1436-1443.
  • 4Koizumi W,Saigenji K,Nakamaru N,et al.Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine hosphorylase/platelet-derived endothelial cell growth factor.Oncology,1999,56:215-222.
  • 5Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med,2001,344:783-792.
  • 6Yu D,Wolf JK,Scanlon M,et al.Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.Cancer Res,1993,53:891-898.
  • 7Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,17:2639-2648.
  • 8Hale RJ, Buckley CJ, Fox H, et al. Prognostic value of C-erbB-2expression in uterine cervical carcinoma [J]. Clin Pathol, 1992, 45(7) :594 -596
  • 9Garcia M, Deroc D, Pujol P, et al. Overexpression of transfected cathepsin-D in transformed cells increases their malignant phenotype and metastatic potency[J]. Oncogene, 1990, 5(12):1809-1816
  • 10Re lf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-l, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis[J]. Cancer Res, 1997, 57(5):963-969

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部